The FINANCIAL — Boehringer Ingelheim on May 26 announced that the U.S. Food and Drug Administration (FDA) approved once-daily Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray.
It has been approved as a long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Stiolto Respimat is not indicated to treat asthma or acute deterioration of COPD, according to Boehringer Ingelheim.
COPD, which includes chronic bronchitis and emphysema, is a serious but treatable lung disease, affecting 210 million people worldwide.1 It is a growing world health priority and is predicted to become the 3rd leading cause of death by 2030.2 Patients are typically diagnosed when lung function is already significantly impaired. COPD symptoms can negatively impact a patient’s ability to breathe especially when performing daily activities.
“A recent review of landmark studies indicates that loss of lung function is more accelerated in the early stages of COPD.5 While no treatment slows the rate of decline, maintenance treatment with Stiolto Respimat initiated at the time of diagnosis will help healthcare providers with their goal of improving lung function,” said Danny McBryan, MD, vice president, Clinical Development & Medical Affairs, Respiratory, Boehringer Ingelheim Pharmaceuticals, Inc.
Discussion about this post